GB-7624: An Investigational Anti-IL-13 Monoclonal Antibody for Atopic Dermatitis

1. Executive Summary

GB-7624 is an investigational monoclonal antibody currently under development by Generate Biomedicines, Inc..[1] Utilizing the company's proprietary artificial intelligence (AI) and machine learning platform for drug generation, GB-7624 is designed to target and inhibit Interleukin-13 (IL-13), a cytokine implicated in the pathophysiology of Type 2 inflammatory diseases.[1] The primary therapeutic indication being pursued for GB-7624 is atopic dermatitis (AD).[1] The program has advanced into clinical development, with a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled study initiated in March 2025.[1] This ongoing trial (NCT06920693 / ACTRN12625000229471), being conducted in healthy adult volunteers in Australia, aims primarily to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending subcutaneous doses of GB-7624.[1] The progression of GB-7624 through clinical trials serves not only to evaluate the therapeutic potential of the antibody itself but also acts as an important validation point for Generate Biomedicines' AI-driven drug discovery and development platform within the competitive immunology landscape.[7] Early safety and PK data from this Phase 1 study will be critical determinants for the future development trajectory of GB-7624 and for reinforcing confidence in the underlying technology platform.

2. Introduction to GB-7624

2.1. Identification

GB-7624 is the development code name for an investigational monoclonal antibody.[1] Known synonyms include GB 7624 and GB7624.[1] It is classified as a biologic drug product.

2.2. Developer

The originator and current developer of GB-7624 is Generate Biomedicines, Inc., a clinical-stage biotechnology company founded by Flagship Pioneering.[1] Generate Biomedicines focuses on applying generative AI, machine learning, and biological engineering principles—collectively termed "The Generate Platform" or "programmable biology"—to accelerate the design and development of novel protein-based therapeutics.[7]

2.3. Therapeutic Area and Indication

The primary therapeutic area targeted by GB-7624 is Immunology and Inflammation, specifically within the sub-categories of Skin and Musculoskeletal Diseases or Congenital Disorders.[1] The specific active indication under investigation is Atopic Dermatitis (AD), also commonly referred to as eczema.[1]

Table 1: GB-7624 Key Information Summary

Feature	Detail	Supporting Snippets
Drug Name	GB-7624	1
Synonyms	GB 7624, GB7624	1
Developer	Generate Biomedicines, Inc.	1
Drug Type	Monoclonal Antibody	1
Target	Interleukin-13 (IL-13)	1
Mechanism	IL-13 inhibitor	1
Therapeutic Area	Immunology	1
Indication	Atopic Dermatitis (AD)	1
Current Phase	Phase 1	1

The selection of Atopic Dermatitis as the initial indication places GB-7624 within a large and well-established therapeutic market. IL-13 is a recognized driver of the Type 2 inflammation central to AD pathogenesis, making it a biologically validated target.[1] However, this field includes existing therapies targeting the IL-13 pathway, such as monoclonal antibodies directly targeting IL-13 (e.g., lebrikizumab, tralokinumab) or its receptor components (e.g., dupilumab targeting IL-4Rα, thereby inhibiting both IL-4 and IL-13 signaling).[12] Consequently, GB-7624 enters a competitive landscape where demonstrating meaningful differentiation will be crucial for its potential success. The advancement of GB-7624, generated via Generate Biomedicines' AI platform, into this validated but crowded space implies an expectation that the molecule possesses advantageous characteristics justifying its development.[7]

3. Mechanism of Action and Rationale

3.1. Target: Interleukin-13 (IL-13)

GB-7624 is specifically designed as an inhibitor of human Interleukin-13 (IL-13).[1] As a monoclonal antibody, it is presumed to bind to IL-13, thereby preventing the cytokine from interacting with its receptors and initiating downstream signaling cascades.

3.2. Role of IL-13 in Atopic Dermatitis

IL-13 is a pleiotropic cytokine primarily produced by T helper 2 (Th2) cells, group 2 innate lymphoid cells (ILC2s), eosinophils, and mast cells. It plays a central role in mediating Type 2 inflammatory responses, which are characteristic features of atopic dermatitis.[12] In the context of AD, IL-13 contributes significantly to skin inflammation, pruritus (itching), and epidermal barrier dysfunction. It promotes the production of IgE by B cells, enhances eosinophil recruitment and activation, and impairs keratinocyte differentiation, leading to defects in the skin barrier that allow for increased allergen penetration and water loss. Clinical studies involving therapies that inhibit IL-13 signaling, either directly or indirectly, have demonstrated efficacy in treating moderate-to-severe AD, confirming the cytokine's critical role in the disease.[12]

3.3. Therapeutic Hypothesis

The therapeutic rationale for GB-7624 in atopic dermatitis is predicated on the targeted inhibition of IL-13. By binding to and neutralizing IL-13, GB-7624 is expected to interrupt the signaling pathways mediated by this cytokine.[1] This blockade is hypothesized to reduce the inflammatory cascade characteristic of AD, leading to improvements in clinical signs (e.g., skin lesions, erythema, edema) and symptoms (e.g., pruritus), and potentially contributing to the restoration of skin barrier function.

3.4. Potential Differentiation

Generate Biomedicines emphasizes the capability of its AI-driven platform to generate novel proteins with optimized properties, potentially leading to differentiated therapeutics.[7] The company has specifically mentioned scaling its platform in immunology with a "highly potent anti-IL-13 monoclonal antibody" for Type 2 inflammation-mediated diseases like atopic dermatitis.[9] While the specific preclinical data supporting claims of differentiation for GB-7624 (e.g., enhanced potency, unique epitope binding, improved pharmacokinetic profile) are not detailed in the provided source materials [3], potential avenues for differentiation could include superior efficacy, an improved safety profile, or a more convenient dosing schedule, such as the six-monthly dosing regimen mentioned as a goal for the company's immunology portfolio.[8] The lack of available comparative preclinical data means that any claims of differentiation for GB-7624 remain speculative at this stage and require substantiation through clinical trial results. Future data releases, particularly from Phase 1 pharmacokinetic and pharmacodynamic assessments (if conducted) and subsequent Phase 2 efficacy studies in AD patients, will be essential to evaluate these potential advantages.

4. Clinical Development Program: Phase 1 Study (NCT06920693 / ACTRN12625000229471)

The initial clinical evaluation of GB-7624 is being conducted in a Phase 1, first-in-human (FIH) study registered under ClinicalTrials.gov identifier NCT06920693 and Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12625000229471.[1]

4.1. Study Overview

• Official & Scientific Title: A Phase 1, First in Human, Randomised, Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Investigate the Safety, Tolerability and Pharmacokinetics of GB-7624 administered subcutaneously in Healthy Adult participants.[5]
• Phase: Phase 1.[1]
• Status: Recruiting (as of March 31, 2025).[1]
• Sponsor: Generate Biomedicines, Inc..[5]
• Health Condition: Healthy Volunteers (Target indication: Atopic Dermatitis).[5]

4.2. Design and Methodology

The trial employs a randomized, double-blind, placebo-controlled design, considered the gold standard for minimizing bias in early clinical evaluation.[5] It is structured into two distinct parts:

• Part A (Single Ascending Dose - SAD): This part evaluates the safety and PK of single doses of GB-7624. A total of 24 healthy volunteers are planned across 3 cohorts.[5]
• Part B (Multiple Ascending Dose - MAD): This part assesses the safety and PK of multiple doses. A total of 16 healthy volunteers are planned across 2 cohorts.[5]

Dose escalation between cohorts within each part, and the progression from Part A to Part B, is guided by reviews from a Safety Review Committee (SRC). The SRC bases its decisions on available blinded safety, tolerability, and PK data from preceding cohorts.[5]

4.3. Objectives

The primary objective of this FIH study is to evaluate the safety and tolerability profile of GB-7624 following single (Part A) and multiple (Part B) subcutaneous administrations in healthy adult volunteers.[5] Key secondary objectives focus on characterizing the pharmacokinetic (PK) profile of GB-7624 and assessing its immunogenicity (the potential to elicit an anti-drug antibody response) after both single and multiple doses.[5] While pharmacodynamic (PD) evaluation is mentioned generally as a goal in the study registration, specific PD endpoints are not listed as primary or secondary outcome measures in the detailed trial record.[5]

4.4. Participant Population

The study enrolls healthy adult volunteers, with an estimated total sample size of 40 participants (24 for SAD, 16 for MAD).[5] Key inclusion criteria require participants to be aged 18 to 65 years, have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m², and be deemed medically healthy based on comprehensive screening assessments including medical history, physical examination, vital signs, ECG, and laboratory tests.[5] Specific thresholds for vital signs (BP, HR, temperature) and ECG parameters (QTcF interval) are defined. Stringent contraception requirements are mandated for females of childbearing potential and sexually active males.[5]

Key exclusion criteria are extensive and designed to minimize confounding factors and ensure participant safety. These include significant medical history across various organ systems, history of malignancy (with exceptions), active infections, positive serology for HIV, HBV, or HCV, recent smoking, substance abuse, severe allergies, use of prohibited medications within specified washout periods, risk factors for cardiac arrhythmias (e.g., long QT syndrome), abnormal liver or kidney function tests, skin conditions interfering with injection site evaluation, recent vaccinations or blood donations, and participation in other clinical trials.[5]

4.5. Intervention Details

Participants are randomized to receive either the active investigational drug, GB-7624, or a matching placebo (0.9% sodium chloride).5 Administration is via subcutaneous (SC) injection, performed by trained study personnel at the clinical site.5

The dose levels planned are:

• Part A (SAD): Single SC doses of 300 mg, 600 mg, or 1200 mg.[5]
• Part B (MAD): Multiple SC doses of either 300 mg or 600 mg, administered on Day 1 and Day 15.[5]

The testing of doses up to 1200 mg (single) and 600 mg (multiple) suggests an anticipation of the need for relatively high therapeutic doses, which is common for monoclonal antibody therapies, or reflects an effort to establish a wide therapeutic window early in development. The resulting PK data will be crucial for determining appropriate dosing regimens for future patient studies.

4.6. Outcome Measures

• Primary Outcomes (Safety & Tolerability): Assessed through the incidence, severity (graded using NCI-CTCAE v5.0), and relationship to study drug of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs leading to discontinuation. Clinically significant changes from baseline in laboratory parameters (hematology, chemistry, coagulation, urinalysis), vital signs, and 12-lead ECGs (including QTcF interval) are also primary measures. Assessments occur continuously from Day 1 through Day 360 (End of Study/Early Termination Visit).[5]
• Secondary Outcomes (Pharmacokinetics): Standard PK parameters will be estimated from serum concentrations of GB-7624, including maximum concentration (Cmax), time to maximum concentration (Tmax), area under the concentration-time curve (AUC, AUClast, AUCinf), terminal half-life (t½), apparent clearance (CL/F), and apparent volume of distribution (V/F). Blood samples for PK analysis are collected at numerous time points from pre-dose through Day 360.[5]
• Secondary Outcomes (Immunogenicity): The incidence rate and titers of anti-drug antibodies (ADA) against GB-7624 will be measured at multiple time points from pre-dose Day 1 through Day 360.[5]

4.7. Timeline and Location(s)

The trial officially commenced with the first participant enrolled on March 28, 2025.[5] The estimated primary completion date and the estimated study completion date are both listed as June 30, 2026.[2] The trial is actively recruiting at Q-Pharm Pty Ltd, located at the Clive Berghofer Research Centre (CBCRC) in Herston, Queensland, Australia.[5] Ethics approval was granted by the Bellberry Human Research Ethics Committee D (Australia) on February 26, 2025.[5] The selection of Australia for this FIH study is a common strategy employed by biotechnology companies, often leveraging the country's relatively efficient clinical trial regulatory pathways and potential R&D tax incentives to expedite early-stage development.[5]

Table 2: Phase 1 Trial (NCT06920693 / ACTRN12625000229471) Key Details

Parameter	Detail	Supporting Snippets
Title	A Phase 1, First in Human, Randomised, Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Investigate the Safety, Tolerability and Pharmacokinetics of GB-7624...	5
Phase	1	1
Status	Recruiting	1
Sponsor	Generate Biomedicines, Inc.	5
Design	Randomized, Double-Blind, Placebo-Controlled, SAD/MAD	5
Population	Healthy Adult Volunteers (Age 18-65)	5
N (Estimated)	40 (24 SAD, 16 MAD)	5
Intervention	GB-7624 (SC): SAD (300, 600, 1200 mg single dose); MAD (300 or 600 mg on Day 1 & 15)	5
Comparator	Placebo (0.9% Sodium Chloride SC)	5
Primary Endpoints	Safety & Tolerability (AEs, Labs, Vitals, ECGs)	5
Key Secondary Endpoints	Pharmacokinetics (PK parameters), Immunogenicity (ADA incidence/titer)	5
Actual Start Date	March 28, 2025	5
Est. Primary Completion	June 30, 2026	2
Est. Study Completion	June 30, 2026	2
Location(s)	Herston, Queensland, Australia (Q-Pharm Pty Ltd)	5

Successful completion of this Phase 1 study, demonstrating an acceptable safety, tolerability, and pharmacokinetic profile, represents the critical next step for GB-7624. Positive outcomes would be necessary to support advancement into Phase 2 trials designed to evaluate efficacy in patients with atopic dermatitis. Conversely, significant safety concerns or unfavorable pharmacokinetic properties could impede or halt further development.

5. Developer Profile: Generate Biomedicines

5.1. Company Overview

Generate Biomedicines, Inc. is a clinical-stage biotechnology company established by Flagship Pioneering.[8] The company operates at the intersection of machine learning, biological engineering, and medicine, positioning itself as a leader in "programmable biology".[7] Its core focus is leveraging generative AI to design and develop novel protein-based therapeutics, including monoclonal antibodies, bispecifics, enzymes, cytokines, CAR-T therapies, and antibody-drug conjugates (ADCs).[4]

5.2. Technology Platform

The company's foundation is "The Generate Platform," an integrated system combining computational power (generative AI, machine learning) with high-throughput experimental capabilities and structural biology (e.g., CryoEM).[7] This platform is designed to move beyond traditional trial-and-error drug discovery towards "drug generation".[9] Generate claims its platform enables the creation of optimized molecules with desired properties, the targeting of historically "undruggable" or difficult targets, and potentially accelerated development timelines.[7] Key capabilities highlighted include de novo protein design (creating proteins without a natural template) and multiparameter co-optimization for properties like potency and stability.[9] The company's significant venture capital funding and large-scale collaborations underscore the high expectations placed on this technology platform.[14]

5.3. Pipeline and Collaborations

Generate Biomedicines is advancing a pipeline across multiple therapeutic areas, primarily immunology/inflammation, oncology, and infectious diseases.[4] Besides GB-7624 (anti-IL-13 for AD), other publicly disclosed clinical-stage assets include GB-0895 (anti-TSLP for severe asthma and COPD) and GB-0669 (an AI-generated anti-SARS-CoV-2 antibody that completed Phase 1).[4] The preclinical portfolio includes programs targeting TL1A, OX40L, IL-23, and various immuno-oncology targets (e.g., CAR-T, ADCs, bispecifics).[4] Generate has established significant collaborations with major pharmaceutical companies, including Amgen (expanded to six programs) and Novartis (potentially worth over $1 billion), focused on leveraging its platform to discover and develop novel protein therapeutics.[9] The clinical progress of internally developed assets like GB-7624 is crucial for validating the platform's capability to translate computational design into clinically viable drug candidates, thereby underpinning the company's valuation and future partnership potential.

6. Potential Significance and Future Outlook

6.1. Positioning in Atopic Dermatitis

GB-7624 targets IL-13, a validated pathway in atopic dermatitis.[1] Success in this market requires demonstrating a competitive advantage over existing therapies that also modulate IL-13 signaling, such as direct IL-13 inhibitors (tralokinumab, lebrikizumab) or IL-4Rα inhibitors (dupilumab).[12] Generate Biomedicines aims for differentiation, potentially through enhanced potency or a less frequent dosing schedule (e.g., six-monthly administration, a stated goal for their I&I portfolio).[8] However, clinical data confirming such advantages are not yet available and will be necessary for GB-7624 to carve out a significant position in the AD treatment landscape.

6.2. Next Steps

The immediate future for GB-7624 hinges on the successful completion of the ongoing Phase 1 trial (NCT06920693 / ACTRN12625000229471).[1] Key milestones include demonstrating acceptable safety and tolerability across the planned dose range and characterizing the drug's pharmacokinetic profile and immunogenicity in healthy volunteers.[5] Generate Biomedicines had previously stated intentions to prepare for a Phase 1 trial in early 2025 [7], aligning with the trial's actual start date in March 2025.[5] Based on the estimated primary completion date of June 2026 [2], initial results from this Phase 1 study might become available in the latter half of 2026 or early 2027. Positive data would pave the way for subsequent Phase 2 studies designed to evaluate the efficacy and safety of GB-7624 in patients with atopic dermatitis.

7. Conclusion

GB-7624 is an investigational anti-IL-13 monoclonal antibody developed by Generate Biomedicines using its generative AI platform technology. It is currently in Phase 1 clinical development for the treatment of atopic dermatitis, with an ongoing FIH trial in healthy volunteers evaluating its safety, tolerability, pharmacokinetics, and immunogenicity.[1] While targeting a validated pathway in AD, GB-7624 faces a competitive landscape and will need to demonstrate clear clinical differentiation, potentially in potency or dosing frequency, in future studies.[8] The successful progression of GB-7624 through clinical development holds significance not only for its potential as a new therapeutic option for AD but also as a critical validation of Generate Biomedicines' AI-driven approach to drug generation.[7] Near-term progress depends on favorable outcomes from the ongoing Phase 1 study.

Works cited

1. GB-7624 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/00628594f6154ed1b73621f01c5b5d66
2. GB-7624 Drug Profile - Ozmosi, accessed April 30, 2025, https://pryzm.ozmosi.com/product/34353
3. GB 7624 - AdisInsight, accessed April 30, 2025, https://adisinsight.springer.com/drugs/800079944
4. Pipeline - Generate:Biomedicines, accessed April 30, 2025, https://generatebiomedicines.com/pipeline
5. Registration - ANZCTR, accessed April 30, 2025, https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12625000229471
6. Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants - ClinicalTrials.Veeva, accessed April 30, 2025, https://ctv.veeva.com/study/study-to-investigate-the-safety-tolerability-and-pharmacokinetics-of-gb-7624-in-healthy-adult-part
7. Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual JP Morgan Healthcare Conference, accessed April 30, 2025, https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline
8. Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html
9. Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual JP Morgan Healthcare Conference, accessed April 30, 2025, https://generatebiomedicines.com/media-center/generatebiomedicines-fortifies-leadership-in-generative-ai
10. Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference - BioSpace, accessed April 30, 2025, https://www.biospace.com/generate-biomedicines-fortifies-leadership-in-generative-ai-with-advancing-clinical-pipeline-and-expanded-amgen-collaboration-overviewed-at-the-42nd-annual-j-p-morgan-healthcare-conference
11. Generate:Biomedicines - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/river/tag/fw_company/Generate%3ABiomedicines
12. Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9977427/
13. GB-7624 - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/river/tag/fw_product/GB-7624
14. Generate Biomedicines, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/organization/4078f43da5ac7d019eacedba42492661
15. Generate:Biomedicines Research by SuperAGI, accessed April 30, 2025, https://sales.superagi.com/company/generate:biomedicines
16. Cendakimab - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/river/tag/fw_product/Cendakimab
17. GB-0895 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/aa3f213f60f141c8a27892eac6c98ca6
18. Next generation of multispecific antibody engineering - Oxford Academic, accessed April 30, 2025, https://academic.oup.com/abt/article/7/1/37/7463325
19. Antibodies as drugs–a Keystone Symposia report - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10103175/
20. Cohen Milstein Discusses Managing Corporate Risk in the AI Gold Rush, accessed April 30, 2025, https://www.cohenmilstein.com/cohen-milstein-discusses-managing-corporate-risk-in-the-ai-gold-rush/
21. Open Positions - Generate:Biomedicines, accessed April 30, 2025, https://generatebiomedicines.com/open-positions
22. Biomarker development for PD-(L)1 axis inhibition - The Journal for ImmunoTherapy of Cancer, accessed April 30, 2025, https://jitc.bmj.com/content/jitc/12/7/e009427.full.pdf
23. Generate:Biomedicines Fortifies Leadership in Generative AI with, accessed April 30, 2025, https://www.nasdaq.com/press-release/generate:biomedicines-fortifies-leadership-in-generative-ai-with-advancing-clinical
24. Ancestral sequence reconstruction of Mic60 reveals a residue signature supporting respiration in yeast - bioRxiv, accessed April 30, 2025, https://www.biorxiv.org/content/10.1101/2024.04.26.591372v1.full.pdf
25. Registration - ANZCTR, accessed April 30, 2025, https://preprod.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=23796&isClinicalTrial=True
26. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06920693
27. Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants | TrialScreen, accessed April 30, 2025, https://app.trialscreen.org/trials/phase-1-to-investigate-safety-tolerability-pharmacokinetics-gb-7624-healthy-trial-nct06920693
28. Zubsolv - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/river/tag/fw_product/Zubsolv
29. cendakimab - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/river/tag/fw_product/cendakimab